{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:11:38Z","timestamp":1793412698244,"version":"4.5.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:00:00Z","timestamp":1668124800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"The European Alliance of Associations for Rheumatology"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1136\/ard-2022-223365","type":"journal-article","created":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T13:25:15Z","timestamp":1668173115000},"page":"95-106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":180,"title":["Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis"],"prefix":"10.1016","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6685-8873","authenticated-orcid":false,"given":"Andreas","family":"Kerschbaumer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1954-0229","authenticated-orcid":false,"given":"Alexandre","family":"Sepriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7136-5248","authenticated-orcid":false,"given":"Sytske Anne","family":"Bergstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef S","family":"Smolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5781-158X","authenticated-orcid":false,"given":"D\u00e9sir\u00e9e","family":"van der Heijde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Caporali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher John","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0340-3580","authenticated-orcid":false,"given":"Patrick","family":"Verschueren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4953-3257","authenticated-orcid":false,"given":"Savia","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1479-5302","authenticated-orcid":false,"given":"Janet E","family":"Pope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1111-8218","authenticated-orcid":false,"given":"Tsutomu","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8242-9262","authenticated-orcid":false,"given":"Kimme L","family":"Hyrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3892-6947","authenticated-orcid":false,"given":"Kevin L","family":"Winthrop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2108-0030","authenticated-orcid":false,"given":"Daniel","family":"Aletaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3073-7284","authenticated-orcid":false,"given":"Tanja A","family":"Stamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1120-4781","authenticated-orcid":false,"given":"Jan W","family":"Schoones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0577-6620","authenticated-orcid":false,"given":"Robert B M","family":"Landew\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2022-223365_bib1","doi-asserted-by":"crossref","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","article-title":"Rheumatoid arthritis","volume":"4","author":"Smolen","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1136\/ard-2022-223365_bib2","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223365_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/annrheumdis-2021-221935","article-title":"2nd Revision eular recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"0","author":"Smolen","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223365_bib4","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/ard-2022-223357","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review Informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"82","author":"Sepriano","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223365_bib5","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/ard-2022-223358","article-title":"Efficacy, duration of use and safety of glucocorticoids: a systematic literature review Informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"82","author":"Bergstra","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223365_bib6","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1136\/annrheumdis-2019-216656","article-title":"Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research Informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis","volume":"79","author":"Kerschbaumer","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223365_bib7","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1136\/annrheumdis-2014-206350","article-title":"2014 update of the EULAR standardised operating procedures for EULAR-endorsed recommendations","volume":"74","author":"van der Heijde","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223365_bib8","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League against rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-223365_bib9","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of rheumatology. Preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-223365_bib10","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1093\/rheumatology\/kez213","article-title":"Effectiveness of different combinations of DMARDs and glucocorticoid bridging in early rheumatoid arthritis: two-year results of CareRA","volume":"58","author":"Stouten","year":"2019","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-223365_bib11","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s00296-021-04994-1","article-title":"Comparison between leflunomide and sulfasalazine based triple therapy in methotrexate refractory rheumatoid arthritis: an open-label, non-inferiority randomized controlled trial","volume":"42","author":"Belani","year":"2022","journal-title":"Rheumatol Int"},{"key":"10.1136\/ard-2022-223365_bib12","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1136\/annrheumdis-2021-220512","article-title":"Comparison of two dose escalation strategies of methotrexate in active rheumatoid arthritis: a multicentre, parallel group, randomised controlled trial","volume":"80","author":"Jain","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223365_bib13","doi-asserted-by":"crossref","first-page":"170","DOI":"10.46497\/ArchRheumatol.2020.7464","article-title":"Efficacy and safety of Opinercept tumor necrosis factor inhibitor therapy for Drug-Refractory rheumatoid arthritis: a randomized clinical trial","volume":"35","author":"Liang","year":"2020","journal-title":"Arch Rheumatol"},{"key":"10.1136\/ard-2022-223365_bib14","doi-asserted-by":"crossref","first-page":"5318","DOI":"10.1093\/rheumatology\/keab153","article-title":"Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study)","volume":"60","author":"Behrens","year":"2021","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-223365_bib15","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1136\/annrheumdis-2021-219876","article-title":"Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study","volume":"81","author":"Nasonov","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223365_bib17","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1136\/annrheumdis-2021-219876","article-title":"Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study","volume":"81","author":"Nasonov","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223365_bib18","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/14397595.2019.1639939","article-title":"Sarilumab monotherapy or in combination with non-methotrexate disease-modifying antirheumatic drugs in active rheumatoid arthritis: a Japan phase 3 trial (HARUKA)","volume":"30","author":"Kameda","year":"2020","journal-title":"Mod Rheumatol"},{"key":"10.1136\/ard-2022-223365_bib19","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1136\/annrheumdis-2021-eular.2443","article-title":"POS0624\u2005efficacy and safety of levilimab in combination with methotrexate in subjects with active rheumatoid arthritis: phase iii, double-blind, placebo-controlled, randomized trial","volume":"80","author":"Mazurov","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223365_bib20","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1136\/annrheumdis-2018-214827","volume":"78","author":"Takeuchi","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223365_bib21","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1136\/annrheumdis-2021-219846","article-title":"Effects of RANKL inhibition on promoting healing of bone erosion in rheumatoid arthritis using HR-pQCT: a 2-year, randomised, double-blind, placebo-controlled trial","volume":"80","author":"So","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223365_bib22","first-page":"732","article-title":"Baricitinib in patients with rheumatoid arthritis with inadequate response to methotrexate: results from a phase 3 study","volume":"38","author":"Li","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard-2022-223365_bib23","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X211006964","volume":"13","author":"Yang","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1136\/ard-2022-223365_bib24","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1002\/art.41384","article-title":"Efficacy and safety of Upadacitinib monotherapy in Methotrexate-Naive patients with Moderately-to-Severely active rheumatoid arthritis (SELECT-EARLY): a multicenter, Multi-Country, randomized, double-blind, active Comparator-Controlled trial","volume":"72","author":"van Vollenhoven","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-223365_bib25","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1093\/rheumatology\/keaa770","article-title":"Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from SELECT-EARLY and SELECT-MONOTHERAPY","volume":"60","author":"Strand","year":"2021","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-223365_bib26","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1093\/rheumatology\/keaa084","article-title":"Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb\/III study","volume":"59","author":"Kameda","year":"2020","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-223365_bib27","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1001\/jama.2019.9055","article-title":"Effect of Filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the finch 2 randomized clinical trial","volume":"322","author":"Genovese","year":"2019","journal-title":"JAMA"},{"key":"10.1136\/ard-2022-223365_bib28","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1136\/annrheumdis-2020-219213","article-title":"Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled finch 3 trial","volume":"80","author":"Westhovens","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223365_bib30","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1056\/NEJMoa2201302","article-title":"Olokizumab versus placebo or adalimumab in rheumatoid arthritis","volume":"387","author":"Smolen","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2022-223365_bib31","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0140-6736(20)32341-2","article-title":"Rituximab versus tocilizumab in anti-TNF inadequate Responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial","volume":"397","author":"Humby","year":"2021","journal-title":"Lancet"},{"key":"10.1136\/ard-2022-223365_bib32","doi-asserted-by":"crossref","first-page":"m4328","DOI":"10.1136\/bmj.m4328","article-title":"Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial","volume":"371","author":"Hetland","year":"2020","journal-title":"BMJ"},{"key":"10.1136\/ard-2022-223365_bib34","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/art.41032","article-title":"Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial","volume":"71","author":"Fleischmann","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-223365_bib35","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1056\/NEJMoa2008250","article-title":"Trial of upadacitinib or abatacept in rheumatoid arthritis","volume":"383","author":"Rubbert-Roth","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2022-223365_bib36","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1136\/annrheumdis-2020-219214","article-title":"Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial","volume":"80","author":"Combe","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223365_bib37","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1080\/14397595.2021.1899591","article-title":"Systematic review and meta-analysis of biosimilar for the treatment of rheumatoid arthritis Informing the 2020 update of the Japan College of rheumatology clinical practice guidelines for the management of rheumatoid arthritis","volume":"32","author":"Tanaka","year":"2022","journal-title":"Mod Rheumatol"},{"key":"10.1136\/ard-2022-223365_bib38","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s40744-020-00259-8","article-title":"Adalimumab biosimilars in the treatment of rheumatoid arthritis: a systematic review of the evidence for Biosimilarity","volume":"8","author":"Huizinga","year":"2021","journal-title":"Rheumatol Ther"},{"key":"10.1136\/ard-2022-223365_bib39","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1136\/annrheumdis-2019-216539","article-title":"Pragmatic randomised controlled trial of very early etanercept and MTX versus MTX with delayed etanercept in RA: the VEDERA trial","volume":"79","author":"Emery","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223365_bib40","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1001\/jama.2021.4172","article-title":"Effect of therapeutic drug monitoring vs standard therapy during infliximab induction on disease remission in patients with chronic immune-mediated inflammatory diseases: a randomized clinical trial","volume":"325","author":"Syversen","year":"2021","journal-title":"JAMA"},{"key":"10.1136\/ard-2022-223365_bib41","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1001\/jama.2021.21316","article-title":"Effect of therapeutic drug monitoring vs standard therapy during maintenance infliximab therapy on disease control in patients with immune-mediated inflammatory diseases: a randomized clinical trial","volume":"326","author":"Syversen","year":"2021","journal-title":"JAMA"},{"key":"10.1136\/ard-2022-223365_bib42","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.semarthrit.2020.05.014","article-title":"Intensive therapy alleviates subclinical synovitis on ultrasound and disease activity and reduces flare in rheumatoid arthritis patients who have achieved clinical target - a randomized controlled trial","volume":"50","author":"Zhao","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard-2022-223365_bib43","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1136\/annrheumdis-2019-215764","article-title":"Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response","volume":"78","author":"Fleischmann","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223365_bib44","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1001\/jama.2021.4542","article-title":"Effect of half-dose vs Stable-Dose conventional synthetic disease-modifying antirheumatic drugs on disease flares in patients with rheumatoid arthritis in remission: the Arctic REWIND randomized clinical trial","volume":"325","author":"Lillegraven","year":"2021","journal-title":"JAMA"},{"key":"10.1136\/ard-2022-223365_bib45","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1093\/rheumatology\/kez470","article-title":"An open-label randomized controlled trial of DMARD withdrawal in RA patients achieving therapeutic response with certolizumab pegol combined with DMARDs","volume":"59","author":"Pope","year":"2020","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-223365_bib46","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/S2665-9913(19)30005-0","article-title":"Methotrexate withdrawal in patients with rheumatoid arthritis who achieve low disease activity with tofacitinib modified-release 11 Mg once daily plus methotrexate (oral shift): a randomised, phase 3b\/4, non-inferiority trial","volume":"1","author":"Cohen","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"10.1136\/ard-2022-223365_bib47","first-page":"1","article-title":"Tapering of etanercept is feasible in patients with rheumatoid arthritis in sustained remission: a pragmatic randomized controlled trial","author":"Bertrand","year":"2021","journal-title":"Scand J Rheumatol"},{"key":"10.1136\/ard-2022-223365_bib48","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1002\/art.40905","article-title":"Reducing or maintaining the dose of subcutaneous tocilizumab in patients with rheumatoid arthritis in clinical remission: a randomized, open-label trial","volume":"71","author":"Sanmarti","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-223365_bib49","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.1016\/S2665-9913(19)30066-9","article-title":"Ultra-Low doses of rituximab for continued treatment of rheumatoid arthritis (REDO study): a randomised controlled non-inferiority trial","volume":"1","author":"Verhoef","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"10.1136\/ard-2022-223365_bib50","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1136\/annrheumdis-2020-eular.1955","article-title":"OP0019\u2005Stable versus tapered and withdrawn treatment with tumor necrosis factor inhibitor in rheumatoid arthritis remission (arctic rewind): A randomised, open-label, phase 4, non-inferiority trial","volume":"79","author":"Lillegraven","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223365_bib51","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1136\/annrheumdis-2020-217246","article-title":"Adalimumab dose tapering in patients with rheumatoid arthritis who are in long-standing clinical remission: results of the phase IV PREDICTRA study","volume":"79","author":"Emery","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223365_bib52","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1136\/annrheumdis-2019-216169","article-title":"Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial","volume":"79","author":"Tanaka","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223365_bib53","article-title":"Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity","volume":"5","author":"Verhoef","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1136\/ard-2022-223365_bib54","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1136\/annrheumdis-2018-214970","article-title":"Gradual tapering TNF inhibitors versus conventional synthetic DMARDs after achieving controlled disease in patients with rheumatoid arthritis: first-year results of the randomised controlled tara study","volume":"78","author":"van Mulligen","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223365_bib55","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1136\/annrheumdis-2020-217485","article-title":"Tapering towards DMARD-free remission in established rheumatoid arthritis: 2-year results of the tara trial","volume":"79","author":"van Mulligen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223365_bib56","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1136\/annrheumdis-2020-217528","article-title":"Two-Year cost effectiveness between two gradual tapering strategies in rheumatoid arthritis: cost-utility analysis of the tara trial","volume":"79","author":"van Mulligen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223365_bib57","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/art.41589","article-title":"Etanercept or methotrexate withdrawal in rheumatoid arthritis patients in sustained remission","volume":"73","author":"Curtis","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-223365_bib59","doi-asserted-by":"crossref","first-page":"e767","DOI":"10.1016\/S2665-9913(21)00220-4","article-title":"Treatment tapering and stopping in patients with rheumatoid arthritis in stable remission (retro): a multicentre, randomised, controlled, open-label, phase 3 trial","volume":"3","author":"Tascilar","year":"2021","journal-title":"Lancet Rheumatol"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724086278?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724086278?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2022-223365","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T04:03:17Z","timestamp":1779249797000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724086278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S0003496724086278"],"URL":"https:\/\/doi.org\/10.1136\/ard-2022-223365","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2022-223365","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 \u00a9 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}